JAKARTA (Reuters) - Indonesia is "finalising" a deal with Merck & Co to procure its experimental antiviral pills, named molnupiravir, to treat COVID-19 ailments, its health minister said on Monday.
Results from a large clinical trial this month showed that the pill, made with Ridgeback Biotherapeutics, cut hospitalisations and deaths by 50%. Merck asked for an emergency use clearance from the United States earlier this month.
Health Minister Budi Gunadi Sadikin told a news conference that the deal is being finalised so that the first shipment of molnupiravir may come at the end of the year after a visit to the company in the U.S.
"So that we have enough stock to withstand a potential next wave," he said, adding that Indonesia and Merck are in talks to build a production plant in Indonesia to produce raw material.
Budi did not say how many pills are being procured. Merck did not immediately respond to a request for comment.
Merck has signed supply deals for the drug with Indonesia's neighbours Malaysia and Singapore, as well as Britain.
Indonesia was Asia's COVID-19 epicentre in July, largely fuelled by the virulent Delta variant, although cases and deaths have largely plummeted recently.
The government said on Monday it is anticipating a potential infection spike brought by the upcoming Christmas holidays.
(Reporting by Stanley Widianto; Editing by Christian Schmollinger)